KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Non-Current Assets (2016 - 2025)

Inovio Pharmaceuticals' Non-Current Assets history spans 15 years, with the latest figure at $15.4 million for Q4 2024.

  • For Q4 2024, Non-Current Assets fell 13.85% year-over-year to $15.4 million; the TTM value through Dec 2024 reached $79.2 million, down 35.43%, while the annual FY2024 figure was $15.4 million, 13.85% down from the prior year.
  • Non-Current Assets for Q4 2024 was $15.4 million at Inovio Pharmaceuticals, down from $16.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $68.6 million in Q4 2020 and bottomed at $15.4 million in Q4 2024.
  • The 5-year median for Non-Current Assets is $47.5 million (2021), against an average of $44.4 million.
  • The largest annual shift saw Non-Current Assets soared 37.89% in 2020 before it plummeted 46.42% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $68.6 million in 2020, then crashed by 30.76% to $47.5 million in 2021, then decreased by 29.91% to $33.3 million in 2022, then tumbled by 46.42% to $17.8 million in 2023, then dropped by 13.85% to $15.4 million in 2024.
  • Per Business Quant, the three most recent readings for INO's Non-Current Assets are $15.4 million (Q4 2024), $16.2 million (Q2 2024), and $17.8 million (Q4 2023).